+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
FEMALE
ID06075953

Evaluating Active Surveillance and Hormonal Therapies for Early Breast Cancer DCIS with Novel Endocrine Treatments

Led by QuantumLeap Healthcare Collaborative · Updated on 2026-10-26

400

Participants Needed

30

Research Sites

260 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating if active surveillance combined with hormonal therapy can effectively manage Ductal Carcinoma In Situ DCIS, an early stage of breast cancer. This Phase 2 trial aims to determine whether new endocrine treatments can increase the number of patients suitable for long-term active surveillance, potentially reducing the need for surgery and radiation that can have significant health effects. Participants will be randomly assigned to receive one of several hormonal therapies standard or low-dose tamoxifen, aromatase inhibitors exemestane, letrozole, anastrozole, or investigational drugs including Testosterone plus Anastrazole pellets, Elacestrant, or Z-endoxifen capsules. Treatments may last up to 36 months or 5 years depending on the therapy. Participants will have MRI evaluations at baseline, 3 months, and 6 months, then mammograms and MRIs alternating every 6 months. If evaluations suggest surgery is needed, participants will stop the study treatment and undergo surgery. During the trial, participants will provide blood samples to assess immune status, saliva samples for genetic testing, and tissue or slides from any surgery done as part of their usual care. Follow-up will continue annually for 10 years. Researchers will monitor adherence, lesion changes via imaging, and quality of life measures. The primary outcome is the number of patients remaining on active surveillance at 7 months, with other outcomes including risk assessment and progression over several years.

CONDITIONS

Brief Title

DCIS: RECAST Trial Ductal Carcinoma In Situ: Re-Evaluating Conditions for Active Surveillance Suitability as Treatment

Research Team

K

Kim Nelson, RN

T

Tammy Neseth, MA, CCRP

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here